Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
NBY's Cash to Debt is ranked higher than
97% of the 774 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.08 vs. NBY: No Debt )
NBY' s 10-Year Cash to Debt Range
Min: 12.67   Max: No Debt
Current: No Debt

Equity to Asset 0.68
NBY's Equity to Asset is ranked higher than
75% of the 725 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.61 vs. NBY: 0.68 )
NBY' s 10-Year Equity to Asset Range
Min: -0.32   Max: 0.83
Current: 0.68

-0.32
0.83
Interest Coverage No Debt
NBY's Interest Coverage is ranked higher than
91% of the 449 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 124.75 vs. NBY: No Debt )
NBY' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 2
Z-Score: -3.40
M-Score: 7.83
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -445.38
NBY's Operating margin (%) is ranked lower than
55% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.25 vs. NBY: -445.38 )
NBY' s 10-Year Operating margin (%) Range
Min: -445.38   Max: 17.47
Current: -445.38

-445.38
17.47
Net-margin (%) -461.37
NBY's Net-margin (%) is ranked lower than
56% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.27 vs. NBY: -461.37 )
NBY' s 10-Year Net-margin (%) Range
Min: -461.37   Max: 17.2
Current: -461.37

-461.37
17.2
ROE (%) -188.37
NBY's ROE (%) is ranked lower than
57% of the 747 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.02 vs. NBY: -188.37 )
NBY' s 10-Year ROE (%) Range
Min: -291.56   Max: 20.21
Current: -188.37

-291.56
20.21
ROA (%) -102.50
NBY's ROA (%) is ranked lower than
57% of the 771 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.09 vs. NBY: -102.50 )
NBY' s 10-Year ROA (%) Range
Min: -102.5   Max: 15.39
Current: -102.5

-102.5
15.39
ROC (Joel Greenblatt) (%) -2156.82
NBY's ROC (Joel Greenblatt) (%) is ranked lower than
54% of the 767 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.47 vs. NBY: -2156.82 )
NBY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2156.82   Max: 111.43
Current: -2156.82

-2156.82
111.43
Revenue Growth (%) -40.20
NBY's Revenue Growth (%) is ranked lower than
53% of the 652 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. NBY: -40.20 )
NBY' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 36.1
Current: -40.2

0
36.1
EBITDA Growth (%) 30.50
NBY's EBITDA Growth (%) is ranked higher than
91% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. NBY: 30.50 )
NBY' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 58.2
Current: 30.5

0
58.2
EPS Growth (%) 32.60
NBY's EPS Growth (%) is ranked higher than
89% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. NBY: 32.60 )
NBY' s 10-Year EPS Growth (%) Range
Min: -33.1   Max: 56.5
Current: 32.6

-33.1
56.5
» NBY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

NBY Guru Trades in

Q2 2013

NBY Guru Trades in Q2 2013

Jim Simons 15,200 sh (New)
» More
Q3 2013

NBY Guru Trades in Q3 2013

Jim Simons Sold Out
» More
Q2 2014

NBY Guru Trades in Q2 2014

Jim Simons 39,500 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with NBY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.33
NBY's P/B is ranked lower than
53% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.42 vs. NBY: 4.33 )
NBY' s 10-Year P/B Range
Min: 1.76   Max: 13.86
Current: 4.33

1.76
13.86
EV-to-EBIT -1.77
NBY's EV-to-EBIT is ranked higher than
51% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.72 vs. NBY: -1.77 )
NBY' s 10-Year EV-to-EBIT Range
Min: 14.9   Max: 81.4
Current: -1.77

14.9
81.4
Current Ratio 6.39
NBY's Current Ratio is ranked higher than
89% of the 560 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.49 vs. NBY: 6.39 )
NBY' s 10-Year Current Ratio Range
Min: 1.34   Max: 10.63
Current: 6.39

1.34
10.63
Quick Ratio 6.28
NBY's Quick Ratio is ranked higher than
89% of the 560 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.77 vs. NBY: 6.28 )
NBY' s 10-Year Quick Ratio Range
Min: 1.34   Max: 10.63
Current: 6.28

1.34
10.63

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.57
NBY's Price/Net Cash is ranked higher than
92% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. NBY: 5.57 )
NBY' s 10-Year Price/Net Cash Range
Min: 2.65   Max: 15.64
Current: 5.57

2.65
15.64
Price/Net Current Asset Value 5.20
NBY's Price/Net Current Asset Value is ranked higher than
89% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. NBY: 5.20 )
NBY' s 10-Year Price/Net Current Asset Value Range
Min: 2.3   Max: 15.64
Current: 5.2

2.3
15.64
Price/Tangible Book 4.33
NBY's Price/Tangible Book is ranked higher than
53% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.20 vs. NBY: 4.33 )
NBY' s 10-Year Price/Tangible Book Range
Min: 1.9   Max: 12.29
Current: 4.33

1.9
12.29
Earnings Yield (Greenblatt) 1.80
NBY's Earnings Yield (Greenblatt) is ranked lower than
58% of the 636 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.70 vs. NBY: 1.80 )
NBY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.2   Max: 6.7
Current: 1.8

1.2
6.7
Forward Rate of Return (Yacktman) -30.98
NBY's Forward Rate of Return (Yacktman) is ranked higher than
50% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.49 vs. NBY: -30.98 )
NBY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -156.4   Max: -21.2
Current: -30.98

-156.4
-21.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
NovaBay Pharmaceuticals, Inc., a Delaware corporation was incorporated on January 19, 2000. The Company was originally incorporated in California as NovaCal Pharmaceuticals, Inc. and subsequently changed its name to NovaBay Pharmaceuticals, Inc. The Company is a clinical-stage biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with its two distinct categories of products namely Aganocide Compounds and NeutroPhase. The Aganocide Compounds led by auriclosene (NVC-422),are patented, synthetic molecules with a broad spectrum of activity against bacteria, viruses and fungi. The Company focuses in three large therapeutic markets namely Dermatology, Ophthalmology, and Urology. The Company also develops another class of molecule, NeutroPhase, which is an FDA 510(k)-cleared product for advanced wound care. Its competitors are Aganocides and for NeutroPhase include large and small pharmaceutical and medical device companies, such as Pfizer, Inc., Johnson & Johnson, Abbott Grp. Plc., GlaxoSmithKline Plc, Sanofi-Aventis SA, Novartis AG, Smith & Nephew Plc, C.R. Bard, Molnlycke, Lohman and Roucher, Johnson and Johnson, 3M, Puricore and Oculus Innovative Sciences. NovaBay, NovaBay Pharma, AgaNase, Aganocide, AgaDerm and NeutroPhase are registered U.S. trademarks of the Company. The testing, manufacturing, labeling, advertising, promotion, distribution, export and marketing of the product candidates are subject to extensive regulation by the FDA, state agencies and comparable regulatory authorities in other countries. In the U.S., the FDA regulates drugs and medical devices under the Federal Food, Drug, and Cosmetic Act and the agency's implementing regulations.
» More Articles for NBY

Headlines

Articles On GuruFocus.com
Own it Feb 29 2012 
NovaBay Pharmaceuticals Inc. (NBY) Chairman Ramin Najafi buys 1,000 Shares Aug 28 2009 
NovaBay Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results Aug 14 2009 

More From Our Partners
Morning Market Losers Aug 20 2014 - BENZINGA

More From Other Websites
Why NovaBay Pharmaceuticals (NBY) Stock Plummeted to a One-Year Low Today Aug 20 2014
Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' Aug 20 2014
NovaBay Announces Results of NVC-422 Phase 2 For Viral Conjunctivitis Aug 20 2014
7:01 am NovaBay Pharma announces its NVC-422 ophthalmic formulation did not meet the primary or... Aug 20 2014
NovaBay Announces Results of NVC-422 Phase 2 for Viral Conjunctivitis Aug 20 2014
NovaBay Announces Results of NVC-422 Phase 2 for Viral Conjunctivitis Aug 20 2014
National Necrotizing Fasciitis Foundation Warns Watch Out For Vibrio Infections Aug 12 2014
NOVABAY PHARMACEUTICALS, INC. Financials Aug 09 2014
NovaBay Pharmaceuticals Reports Second Quarter 2014 Financial Results and a Clinical/Business Update Jul 31 2014
NovaBay Pharmaceuticals Reports Second Quarter 2014 Financial Results and a Clinical/Business Update Jul 31 2014
NOVABAY PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report Jul 31 2014
In RadioMD Interview, Dr. John Crew Describes Successful New Treatment for Flesh-Eating Disease Jul 24 2014
NovaBay Pharmaceuticals Announces Direct US Marketing-Sales Campaign For New i-LidTM Cleanser... Jul 16 2014
NovaBay Pharmaceuticals Announces Direct US Marketing-Sales Campaign for New i-LidTM Cleanser... Jul 16 2014
Letter to NovaBay Shareholders Jul 10 2014
Letter to NovaBay Shareholders Jul 10 2014
Letter to NovaBay Shareholders Jul 10 2014
NovaBay’s New Product for Serious Eye Conditions Highlighted in CEOLIVE.TV Interview Jul 03 2014
NovaBay’s New Product for Serious Eye Conditions Highlighted in CEOLIVE.TV Interview Jul 03 2014
British Prime Minister David Cameron Warns of Growing Crisis of Antibiotic-Resistant Bacteria, But... Jul 02 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide